The Experiences of Patients Living With Malignant Pleural Effusions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03235999|
Recruitment Status : Recruiting
First Posted : August 1, 2017
Last Update Posted : August 2, 2018
|Condition or disease|
|Malignant Pleural Effusion|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||The Experiences of Patients Living With Malignant Pleural Effusions|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
Up to 10 patients who have had talc pleurodesis
Up to 10 patients who have had indwelling pleural catheters (IPC)
- Patient Experiences of living with malignant pleural effusion and different pleural procedures [ Time Frame: 4 weeks after IPC placement or talc pleurodesis ]
Qualitative interviews - Interviews will be recorded on a digital audio recorder and then downloaded on to a password protected computer. The interviews will then be sent for transcription using secure email and anonymised.
We will perform thematic analysis on the interview data. This is a process to help explore the experiences of the subject as they describe it rather than looking at how they talk about the experience. Themes will be drawn from the data following coding. Common codes relating to a theme, for example pain, will be identified and examples of text used to demonstrate the theme extracted. This will ensure a wide variety of quotes across the interviews rather than focusing on one main or a subset of interviews. We will use an inductive approach whereby themes will emerge and not be developed in advance. Emerging codes will be checked by the supervisory team.
There will be no numerical, quantitative data for analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03235999
|Contact: Mark Walker||+44300 email@example.com|
|Gloucestershire Hospitals NHS Foundation Trust||Recruiting|
|Cheltenham, Gloucestershire, United Kingdom, GL53 7AN|
|Contact: Mark Walker +44300 4225463 firstname.lastname@example.org|
|Principal Investigator:||Paul Perkins, MBBCh||Gloucestershire Hospitals NHS Foundation Trust|